Answers are grounded in this paper and cite their sources.
// Meijun Du 1, * , Karthik V. Giridhar 2, * , Yijun Tian 1, 3 , Michael R. Tschannen 4 , Jing Zhu 1 , Chiang-Ching Huang 5 , Deepak Kilari 6 , Manish Kohli 2 and Liang Wang 1 1 Department of Pathology and MCW Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA 2 Department of Oncology, Mayo Clinic, Rochester, MN, USA 3 Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China 4 Human and Molecular Genetics Center, Medical College of Wisconsin, Milwaukee, WI, USA 5 Department of Biostatistics, University of Wisconsin, Milwaukee, WI, USA 6 Department of Oncology, Medical College of Wisconsin and Milwaukee VA Medical Center, Milwaukee, WI, USA * These authors have contributed equally to this work Correspondence to: Liang Wang, email: liwang@mcw.edu Manish Kohli, email: kohli.manish@mayo.edu Keywords: metastatic renal cell cancer, exosomal miRNA, overall survival, biomarker Received: March 28, 2017 Accepted: June 19, 2017 Published: July 22, 2017 ABSTRACT Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ~3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays. Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54). A multivariate analysis of miR-let-7i-5p with the clinical factor-based Memorial Sloan-Kettering Cancer Center (MSKCC) score improved survival prediction from an area under the curve (AUC) of 0.58 for MSKCC score to an average AUC of 0.64 across 48-month follow-up time. The multivariate model was able to define a high-risk group with median survival of 14 months and low risk group of 39 months (P=0.0002, HR=3.43, 95%CI, 2.73-24.15). Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC.
No takes yet. Share an insight, caveat, or question.
Du et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: